Tony Hagen is senior managing editor for The Center for Biosimilars®.
China's National Medical Products Administration (NMPA) has cleared Innovent Biologics' adalimumab biosimilar for more indications.
China’s National Medical Products Administration (NMPA) has approved Innovent Biologics’ adalimumab injection biosimilar (Sulinno) for new indications: pediatric plaque psoriasis and noninfectious intermediate uveitis, posterior uveitis, and panuveitis in adults for whom corticosteroid therapy may be inappropriate or ineffective.
Sulinno was previously approved by the NMPA for rheumatoid arthritis, ankylosing spondylitis, psoriasis and polyarticular juvenile idiopathic arthritis. Those approvals were issued in September 2020.
"There remains huge unmet medical need for the treatment of psoriasis and uveitis in China,” Qian Lei, senior director of Medical Sciences and Strategies of Special Diseases for Innovent, said in a statement, explaining the value of this medicine.
Psoriasis is a skin disease characterized by accelerated growth of skin surface cells, resulting in pain and psychological burden. Uveitis is a type of eye inflammation that can increase risk for glaucoma, macular edema, and cataracts.